Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Mar 1;110(3):223-231.
doi: 10.1093/jnci/djx285.

International Cognition and Cancer Task Force Recommendations for Neuroimaging Methods in the Study of Cognitive Impairment in Non-CNS Cancer Patients

Affiliations

International Cognition and Cancer Task Force Recommendations for Neuroimaging Methods in the Study of Cognitive Impairment in Non-CNS Cancer Patients

Sabine Deprez et al. J Natl Cancer Inst. .

Abstract

Cancer- and treatment-related cognitive changes have been a focus of increasing research since the early 1980s, with meta-analyses demonstrating poorer performance in cancer patients in cognitive domains including executive functions, processing speed, and memory. To facilitate collaborative efforts, in 2011 the International Cognition and Cancer Task Force (ICCTF) published consensus recommendations for core neuropsychological tests for studies of cancer populations. Over the past decade, studies have used neuroimaging techniques, including structural and functional magnetic resonance imaging (fMRI) and positron emission tomography, to examine the underlying brain basis for cancer- and treatment-related cognitive declines. As yet, however, there have been no consensus recommendations to guide researchers new to this field or to promote the ability to combine data sets. We first discuss important methodological issues with regard to neuroimaging study design, scanner considerations, and sequence selection, focusing on concerns relevant to cancer populations. We propose a minimum recommended set of sequences, including a high-resolution T1-weighted volume and a resting state fMRI scan. Additional advanced imaging sequences are discussed for consideration when feasible, including task-based fMRI and diffusion tensor imaging. Important image data processing and analytic considerations are also reviewed. These recommendations are offered to facilitate increased use of neuroimaging in studies of cancer- and treatment-related cognitive dysfunction. They are not intended to discourage investigator-initiated efforts to develop cutting-edge techniques, which will be helpful in advancing the state of the knowledge. Use of common imaging protocols will facilitate multicenter and data-pooling initiatives, which are needed to address critical mechanistic research questions.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Main recommendations and considerations for incorporation of neuroimaging into studies of cognitive impairment in non–central nervous system cancer patients. IRB = institutional review board; MRI = magnetic resonance imaging; PET = positron emission tomography.

References

    1. Koppelmans V, Breteler MMB, Boogerd W et al. , Neuropsychological performance in survivors of breast cancer more than 20 years after adjuvant chemotherapy. J Clin Oncol. 2012;3010:1080–1086. 10.1200/JCO.2011.37.0189 - DOI - PubMed
    1. de Ruiter MB, Reneman L, Boogerd W et al. , Cerebral hyporesponsiveness and cognitive impairment 10 years after chemotherapy for breast cancer. Hum Brain Mapp. 2011;328:1206–1219. 10.1002/hbm.21102 - DOI - PMC - PubMed
    1. Wefel JS, Kesler SR, Noll KR et al. , Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adults. CA Cancer J Clin. 2015;652:123–138. 10.3322/caac.21258 - DOI - PMC - PubMed
    1. Correa DD, Ahles TA.. Neurocognitive changes in cancer survivors. Cancer J. 2008;146:396–400. 10.1097/PPO.0b013e31818d8769 - DOI - PubMed
    1. Dietrich J, Monje M, Wefel J et al. , Clinical patterns and biological correlates of cognitive dysfunction associated with cancer therapy. Oncologist. 2008;1312:1285–1295. 10.1634/theoncologist.2008-0130 - DOI - PubMed

Publication types

MeSH terms